UCB Presents Nine Abstracts at EADV 2020, Showcasing Ongoing Commitment to Dermatology
First results from the Phase 3 BE SURE study will be presented showing superior skin clearance with bimekizumab compared to Humira® (adalimumab) in patients with moderate-to-severe plaque psoriasis Two oral presentations from the Phase 3 BE VIVID study show consistent levels of skin clearance with bimekizumab irrespective of patient demographics, disease characteristics and prior treatment experi